目的 探讨苓桂咳喘宁胶囊联合沙美特罗替卡松气雾剂治疗慢性阻塞性肺疾病急性加重期的临床疗效。方法 选取2017年2月-2018年8月河南中医药大学第三附属医院收治的慢性阻塞性肺疾病急性加重期患者108例作为研究对象，按照随机数字表法分为对照组和治疗组，每组各54例。对照组雾化吸入沙美特罗替卡松气雾剂，1揿/次，2次/d。治疗组在对照组治疗的基础上口服苓桂咳喘宁胶囊，5粒/次，3次/d。两组患者均连续治疗14 d。观察两组的临床疗效，比较两组的肺功能以及C反应蛋白（CRP）、降钙素（PCT）、丙二醛（MDA）、超氧化物歧化酶（SOD）水平。结果 治疗后，对照组和治疗组的总有效率分别为77.78%、92.59%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组的第一秒用力呼气容积（FEV1）、FEV1/用力肺活量（FVC）、第一秒用力呼气容积占预计值（FEV1% pred）均显著升高，同组治疗前后差异具有统计学意义（P<0.05）；且治疗后治疗组的FEV1、FEV1/FVC、FEV1% pred均明显高于对照组，两组差异具有统计学意义（P<0.05）。治疗后，两组的CRP、PCT、MDA水平均显著降低，SOD水平显著升高，同组治疗前后差异具有统计学意义（P<0.05）；且治疗后治疗组的CRP、PCT、MDA水平比对照组低，SOD比对照组高，两组差异有统计学意义（P<0.05）。结论 苓桂咳喘宁胶囊联合沙美特罗替卡松气雾剂治疗慢性阻塞性肺疾病急性加重期具有较好的临床疗效，能改善肺功能，调节CRP、PCT、MDA、SOD水平，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Linggui Kechuanning Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods Patients (108 cases) with acute exacerbation of chronic obstructive pulmonary disease in Third Affiliated Hospital of Henan University of Traditional Chinese Medicine from February 2017 to August 2018 were randomly divided into control and treatment groups, and each group had 54 cases. Patients in the control group were atomization inhalation administered with Salmeterol Xinafoate and Fluticasone Propionate Aerosol, 1 press/time, once daily. Patients in the treatment group were po administered with Linggui Kechuanning Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and pulmonary function and the levels of CRP, PCT, MDA and SOD in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.78% and 92.59%, respectively, and there was difference between two groups (P < 0.05). After treatment, FEV1, FEV1/FVC, and FEV1% pred in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the pulmonary function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of CRP, PCT, and MDA in two groups were significantly decreased, but the levels of SOD in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Linggui Kechuanning Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol has clinical curative effect in treatment of acute exacerbation of chronic obstructive pulmonary disease, can improve pulmonary function, and regulate the levels of CRP, PCT, MDA and SOD, which has a certain clinical application value.

河南省科技发展计划项目（172102310052）